BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, July 24, 2026
Breaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaBreaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Cancer

Hengrui scientists patent new PARP-1 inhibitors

March 20, 2024
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Read More
Illustration of tau proteins in Alzheimer's disease
Neurology/Psychiatric

PAV-174 inhibits tau protein phosphorylation and aggregation in vitro

March 20, 2024
Prosetta Biosciences Inc. has presented data on small molecules that inhibit cellular host factors needed for viral replication as a discovery tool to identify molecular interfaces upstream of Alzheimer’s disease cellular pathology.
Read More
Brain illustration
Neurology/Psychiatric

TREM2 agonist VG-3927 boosts microglial repair functions in models of AD

March 20, 2024
It has been previously demonstrated that genetic loss-of-function of triggering receptor expressed on myeloid cells 2 (TREM2) impairs microglia migration, with the TREM2 R47H variant having been linked to increased risk of Alzheimer’s disease (AD) due to impaired microglia clustering and enhanced neuronal damage.
Read More
Brain and DNA
Neurology/Psychiatric

Depymed’s DPM-1003 receives IND clearance for Rett syndrome evaluation

March 20, 2024
Depymed Inc. has received FDA clearance to initiate a phase I trial for DPM-1003 for the treatment of Rett syndrome.
Read More
Skin irritation on hands
Dermatologic

Rigel’s new skin-penetrant IRAK-1/4 inhibitor shows promise for psoriasis

March 20, 2024
Rigel Pharmaceuticals Inc. presented findings from collaborative work with Medpharm that identified R-209, an interleukin-1 receptor-associated kinase 1 and 4 (IRAK-1/4) inhibitor with optimized properties for topical application.
Read More
Inflammatory

Identification of highly potent, selective, orally bioavailable Gal-3 inhibitors

March 20, 2024
Idorsia Pharmaceuticals Ltd. has reported the discovery of novel galectin-3 (Gal-3) inhibitors for the potential treatment of fibrotic and inflammatory diseases. Galactins are a family of glycan-binding proteins associated with various biological processes, including apoptosis, inflammation, fibrosis, angiogenesis, immunomodulation or tumor proliferation.
Read More
Lab mouse
Gastrointestinal

KEAP1 C151 inhibitor VVD-702 ameliorates experimental colitis in mice

March 20, 2024
Nuclear factor erythroid 2-related factor 2 (NRF2) is a master regulator of cytoprotective mechanisms, and the cellular levels of this transcription factor are maintained low under normal conditions via actions of a CUL3-based E3 ligase, Kelch-like ECH-associated protein 1 (KEAP1).
Read More
Heart, DNA and ECG
Cardiovascular

SBT-589 shows cardioprotective effects in mouse model of FA cardiomyopathy

March 20, 2024
Stealth Biotherapeutics Inc. has presented new data demonstrating cardioprotective effects of SBT-589 in preclinical models of Friedreich’s ataxia (FA). SBT-589 acts on mitochondrial pathways essential for cellular health and energy production that are impaired in FA cardiomyopathy.
Read More
Infection

Merck & Co. reports discovery of oral 3CLpro inhibitor for coronavirus infection at ACS

March 20, 2024
Merck & Co. has revealed the discovery of novel oral SARS-CoV-2 3C-like proteinase (3CLpro; Mpro) inhibitors for the potential treatment and/or prophylaxis of COVID-19. 3CLpro plays a key role in viral life cycle by cleaving viral protein and helps in replication and infection, which make 3CLpro a target for designing drugs to treat COVID-19.
Read More
Candida albicans infection
Infection

Commensal yeast species prevents candidiasis

March 20, 2024
By Mar de Miguel
Scientists at the Weizmann Institute of Science in Israel announced the discovery of the new intestinal microbiota species Kazachstania weizmannii in mice, which competed with and limited the growth of Candida albicans, thus preventing candidiasis. Both microorganisms belong to the Saccharomycetaceae family and reside in humans, maintaining a complex interaction with therapeutic value.
Read More
Previous 1 2 … 835 836 837 838 839 840 841 842 843 … 18135 18136 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2026.
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 21, 2026
  • Tree in the shape of human head losing leaves

    KBN-2201 reverses key features of Alzheimer’s in mice

    BioWorld Science
    Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.
  • Click chemistry drug bound to pancreatic cancer cells from mice

    In vivo click ADCs could address tumor heterogeneity

    BioWorld
    Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing